SUSQUEHANNA INTERNATIONAL GROUP, LLP
Position in ENGN — enGene Therapeutics Inc.
CIK 1446194
BALA CYNWYD, PA
Position in ENGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$42,333
New position
Shares Held
24,470
first reported quarter
Ownership
0.037%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#45
of 60 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ENGN
reported options exposure · as of Jun 30, 2026CallValue
$107,087
CallShares
61,900
PutValue
$541,663
PutShares
313,100
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026SUSQUEHANNA INTERNATIONAL GROUP, LLP holds $1,650,012,247 across 349 Biotechnology names. ENGN ranks #299 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,053,896 | $140,442,180 | |
| 2 | CYTK |
Cytokinetics Inc
|
1,549,458 | $131,998,327 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
180,219 | $112,373,755 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
294,460 | $88,641,293 | |
| 5 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
148,610 | $79,796,139 | |
| 6 | INSM |
INSMED Inc
|
729,354 | $77,763,723 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
144,174 | $71,615,550 | |
| 8 | AGIO |
Agios Pharmaceuticals, Inc.
|
1,375,558 | $51,046,957 |
All Filings in ENGN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $541,663 | 313,100 | Put | Other | 2026-08-14 | |
| 2026-06-30 | $107,087 | 61,900 | Call | Other | 2026-08-14 | |
| 2026-06-30 | $42,333 | 24,470 | Shares | Other | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||